This is the assessment of the relative effectiveness of "Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing".

We are pleased to announce that the CA of JA3 WP4 on “Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing.” is now available.

The purpose of the assessment is to evaluate the relative effectiveness and safety of noninvasive prenatal testing (NIPT) for the screening of fetal trisomy 21, trisomy 18 and trisomy 13 in comparison to first trimester combined screening, evaluating the potential benefits and risks of the different  screening pathways.

Find the documentation provided by the authoring team here.